CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Jan. 11, 2024—BioMérieux has acquired the entire share capital of software company Lumed, increasing its stake from 16 to 100 percent. The acquisition of 84 percent of the capital represents an investment of about €9 million. Lumed, based in Sherbrooke, Quebec, developed a clinical decision support system to help hospitals optimize antimicrobial prescriptions and monitor health-care–associated infections.
“Today, many hospitals around the world are structuring themselves around the major issue of antimicrobial resistance and infection prevention. With Lumed, we provide solutions for antimicrobial stewardship teams to improve their daily workflow,” Jennifer Zinn, BioMérieux’s executive vice president of clinical operations, said in a press statement. “The software contributes to optimizing the process of care delivery, as well as costs and patient management.”
Tagged with: BioMerieux